Paris, July 19, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company
dedicated to the development of orphan oncology products and supportive care products,
announces a successful capital increase, with maintenance of preferential subscription rights,
launched on July 2, 2013, and which will enable the Company to raise €8.74 million, after
implementation of the extension clause.
“The great success of our capital increase achieved in a tough market environment represents
an important vote of confidence by our shareholders, and especially Financière de la Montagne
and IDInvest, who have provided significant support to BioAlliance Pharma in this transaction”
comments Judith Greciet, CEO of BioAlliance Pharma. “We would like to thank them and all of
the shareholders and investors who have subscribed to this transaction.”
The amount raised will enable BioAlliance Pharma to accelerate two major clinical trials in its
oncology products portfolio:
“These two drugs’ development progress represents key value drivers for BioAlliance Pharma”
adds Judith Greciet. “Thanks to this financing, we can expand the number of investigator
centers involved in both studies, increase patient recruitment and optimize development
timelines of Validive, which should complete phase II in 2014, and of Livatag.”
Details of the capital increase
The subscription period was from the July 2 to 12, 2013.
The total request has reached 3,52 millions of shares for a global amount of 12,3 millions euros,
representing a subscription rate of 155%. The Chief Executive Officer has decided to fully
implement the extension clause, thereby bringing the number of offered shares from 2.269.964
The gross amount of the capital increase, which has been oversubscribed, is 8.739.360 euros
and implies the creation of 2.496.960 new shares after the implementation of the extension
1.862.653 new shares have been subscribed on an irreducible basis, representing around 75%
of new shares to be issued after exercice of the extension clause. The demand on a reducible
basis accounted for 1.656.467 new shares and thus will be partially allocated up to 634.307 new
The share capital will thus be increased from €4.539.928,75 to €5 164 168,75 divided into
20 656 675 shares at €0.25 nominal value per share.
The settlement and delivery of the new shares will occur on July 24, 2013 and 2.496.960 new
shares will be listed on NYSE Euronext Paris on July 25, 2013 on the same listing line as the
existing shares of the company (FR0010095596).
Partner of the transaction
BioAlliance Pharma thanks Invest Securities in this capital increase transaction.
Conseil Chef de file et Teneur de Livre